TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8981340

Group type: EXPERIMENTAL
Intervention: New matrix patch for estradiol delivery (active patch)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patch (control)
Number of subjects: 20
Study: 1442910

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard obstetric care without amnioinfusion
Number of subjects: 170
Study: 3838924

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine hydrochloride (B10 group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 15 ml of 0.5% bupivacaine hydrochloride (B15 group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All groups (B10, B15, and control) at 3-4 days post-operative
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All groups (B10, B15, and control) at 10-15 days post-operative
Number of subjects: 14
Study: 31745072

Group type: EXPERIMENTAL
Intervention: High-dose eicosapentaenoic acid (EPA, 1.2g)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 30170170

Group type: COMPARATOR
Intervention: Hypoxia (H)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exercise under Hypoxia (EH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normoxia (N)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exercise under Normoxia (EN)
Number of subjects: 40
Study: 27094054

Group type: EXPERIMENTAL
Intervention: 3D 0° HD endoscope
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 3D 0° SD endoscope
Number of subjects: 46

Group type: COMPARATOR
Intervention: 2D 0° HD endoscope
Number of subjects: 46
Study: 24621587

Group type: EXPERIMENTAL
Intervention: Standard care and gum chewing (n = 13)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard postoperative care (n = 18)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard care and a silicone‐adhesive patch (attention control) (n = 16)
Number of subjects: 47
Study: 22964160

Group type: EXPERIMENTAL
Intervention: T3 (25 μg/day in week 1 and increasing to 50 μg/day in week 2) plus sertraline
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 153
Study: 20543729

Group type: EXPERIMENTAL
Intervention: Creatine loading (20 packets of 5 g Cr citrate, 18 g dextrose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (20 packets of 18 g dextrose)
Number of subjects: 50
Study: 18035158

Group type: EXPERIMENTAL
Intervention: Vaccination reminders to parents during hospitalization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study: 16272184

Group type: EXPERIMENTAL
Intervention: Caffeine (1.5mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11891025

Group type: EXPERIMENTAL
Intervention: Systematic nodal dissection (SND)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Mediastinal lymph nodal sampling (MLS)
Number of subjects: 532
Study: 10073514

Group type: EXPERIMENTAL
Intervention: Iron cooking pots
Number of subjects: 407

Group type: COMPARATOR
Intervention: Aluminium cooking pots
Number of subjects: 407
Study: 8847044

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy with G-CSF
Number of subjects: 30

Group type: COMPARATOR
Intervention: G-CSF therapy
Number of subjects: 30
Study: 2202706

Group type: EXPERIMENTAL
Intervention: Oral propranolol (administered to 15 patients, dosage adjusted to reduce resting heart rate by approximately 25%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (matched group of 15 control subjects)
Number of subjects: 30
Study: 6896965

Group type: EXPERIMENTAL
Intervention: Epidural administration of morphine 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal application of morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural or intrathecal opiate
Number of subjects: 0
Study: 31829095

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow mesenchymal stem cells (MSCINJ) with intensive atorvastatin (80 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine atorvastatin (20 mg/d) with placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracoronary infusion of autologous bone marrow mesenchymal stem cells (MSCINJ) with placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Routine atorvastatin (20 mg/d) with MSCINJ
Number of subjects: 100
Study: 30175557

Group type: EXPERIMENTAL
Intervention: High CHO (HCHO: 415 g) during recovery and moderate-intensity exercise (120SS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low CHO (LCHO: 80 g) during recovery and moderate-intensity exercise (120SS)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (HCHO and LCHO) after 120SS
Number of subjects: 28
Study: 27333959

Group type: EXPERIMENTAL
Intervention: Canned tangerines (234-304g)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pink grapefruit (60-540g)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Canned tangerines (234g)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pink grapefruit (540g)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Canned tangerines (234-304g) or Pink grapefruit (60-540g)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Canned tangerines (234g) or Pink grapefruit (540g)
Number of subjects: 19
Study: 24510942

Group type: EXPERIMENTAL
Intervention: 5-month educational intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 58
Study: 20662675

Group type: EXPERIMENTAL
Intervention: Local infiltrations of 1 mL articaine HCl 4% with epinephrine 1/200,000 to the ipsilateral mylohyoid and buccal nerves
Number of subjects: 14

Group type: COMPARATOR
Intervention: Inferior alveolar and buccal nerve blocks
Number of subjects: 14
Study: 19427768

Group type: EXPERIMENTAL
Intervention: Intensive treatment (mean HbA1c reduction of 0.9%)
Number of subjects: 32629
Study: 17228043

Group type: EXPERIMENTAL
Intervention: VTrim (therapist-led structured behavioral weight loss program)
Number of subjects: 124

Group type: COMPARATOR
Intervention: eDiets.com (self-help commercial online weight loss program)
Number of subjects: 124
Study: 14635010

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b 3 MU/day for 24 weeks, followed by 3 MU x 3/week for 24 weeks plus ribavirin 1-1.2 g/day for 48 weeks
Number of subjects: 106
Study: 11859274

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (12-week ergocycle program at 60% VO2 peak, one hour thrice a week)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (obese subjects)
Number of subjects: 13
Study: 10462926

Group type: EXPERIMENTAL
Intervention: Exercise training program at 50% of peak oxygen uptake for eight weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not exercised)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 22
Study: 7608347

Group type: EXPERIMENTAL
Intervention: Group interpersonal therapy (IPT) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only control group (waiting-list)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) for 12 weeks
Number of subjects: 0
Study: 2678309

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + hydrochlorothiazide 15 mg/die
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg/die
Number of subjects: 0
Study: 778518

Group type: EXPERIMENTAL
Intervention: Innovar (droperidol 5 mg, fentanyl 0.1 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inapsine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31081281

Group type: EXPERIMENTAL
Intervention: Sutured management (TEM-S)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open management (TEM-O)
Number of subjects: 50
Study: 28251399

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 39
Study: 25257616

Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy (RSWT) - four sessions, once weekly
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 23306956

Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted esophagectomy (LAE)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Open surgery (OE)
Number of subjects: 86
Study: 21548932

Group type: EXPERIMENTAL
Intervention: Data quality review process
Number of subjects: 1595

Group type: COMPARATOR
Intervention: Countries with ≤ 25 recruited subjects
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Countries with low recruiting and high recruiting
Number of subjects: 1595
Study: 18163165

Group type: EXPERIMENTAL
Intervention: MTX plus FA (20 mg/week) for 16 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: MTX monotherapy for 16 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MTX plus FA (20 mg/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 20
Study: 16864756

Group type: EXPERIMENTAL
Intervention: Diet 1 (high carbohydrate, high GI)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Diet 2 (high carbohydrate, low GI)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Diet 3 (high protein, high GI)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Diet 4 (high protein, low GI)
Number of subjects: 129
Study: 12869379

Group type: EXPERIMENTAL
Intervention: 2-week oral treatment with 3 x 5 mg/day terbutaline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (homozygous wild-type beta2ARs)
Number of subjects: 16
Study: 11533316

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (enteral or parenteral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9744273

Group type: EXPERIMENTAL
Intervention: Prism adaptation to a rightward optical deviation
Number of subjects: 0
Study: 8040808

Group type: EXPERIMENTAL
Intervention: Test socks (21% stretch nylon and 80% synthetic hollow‐core fiber)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control socks (cotton or cotton/acrylic)
Number of subjects: 21
Study: 2647043

Group type: EXPERIMENTAL
Intervention: ethamsylate
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 1195163

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple mastectomy with radical radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment options
Number of subjects: 0
Study: 30990245

Group type: EXPERIMENTAL
Intervention: BuMA SES
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Excel SES
Number of subjects: 2348
Study: 30700375

Group type: EXPERIMENTAL
Intervention: Self-management group using a website with goal-setting strategy and storytelling schema
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Knowledge-only group with access to the website
Number of subjects: 524

Group type: COMPARATOR
Intervention: Control group with only lectures and no website access
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Self-management group
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Intervention overall
Number of subjects: 524
Study: 28399638

Group type: EXPERIMENTAL
Intervention: TTFields plus chemotherapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 204
Study: 25605698

Group type: EXPERIMENTAL
Intervention: DEX-INF (local infiltration of dexamethasone 0.5 mg/kg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: DEX-IV (intravenous injection of dexamethasone 0.5 mg/kg, maximum dose 24 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: DEX-INF
Number of subjects: 240

Group type: COMPARATOR
Intervention: DEX-IV
Number of subjects: 240
Study: 23031323

Group type: EXPERIMENTAL
Intervention: Purebred rabbits at 30°C
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Crossbred rabbits at 30°C
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ambient temperature increase
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Purebred rabbits
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 96
Study: 21519586

Group type: EXPERIMENTAL
Intervention: Rosa damascena mouthwash
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19348923

Group type: EXPERIMENTAL
Intervention: Individualized self-management education
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care with self-monitoring alone
Number of subjects: 95
Study: 16766441

Group type: EXPERIMENTAL
Intervention: Intensive hypnotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 20
Study: 14758577

Group type: EXPERIMENTAL
Intervention: Olanzapine 7.5 mg/day
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg/day
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 11719736

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 8 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg 4 times daily on day 8
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9407259

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (21 g.day-1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 18
Study: 29430142

Group type: EXPERIMENTAL
Intervention: Metal laser sintering (MLS) technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lost-wax (LW) technique
Number of subjects: 40
Study: 27346078

Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 90 g/day (multiple-serving study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 50 g/day (single-dose study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polydextrose at 90 g (positive control, multiple-serving study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polydextrose at 50 g (positive control, single-dose study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 30 g (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corn starch fiber at 60 g (multiple servings)
Number of subjects: 0
Study: 24969408

Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MAD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 32
Study: 22871048

Group type: EXPERIMENTAL
Intervention: Polyherbal Unani formulation (topical application)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sodium thiosulphate lotion (20%) (control group)
Number of subjects: 46
Study: 19489496

Group type: EXPERIMENTAL
Intervention: Moxibustion on temperature-sensitive points, once each day for one course (7 days).
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional moxibustion at specific points (Jiaji, Ciliao, Zhibian, Huantiao, Weizhong, Yanglingquan, Kunlun), once each day for one course (7 days).
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moxibustion on temperature-sensitive points (after 6 months follow-up).
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional moxibustion (after 6 months follow-up).
Number of subjects: 120
Study: 17091134

Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction (CA) toothbrush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colgate Navigator (NA) toothbrush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crest SpinBrush Pro (SBP) toothbrush
Number of subjects: 60
Study: 15525254

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 11567957

Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml applied four times daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Latanoprost 50 microg/ml applied once daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml applied once daily after 3 weeks without treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single drop of latanoprost on day 50
Number of subjects: 28
Study: 9671017

Group type: EXPERIMENTAL
Intervention: Combined physical and mental stress testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical exercise alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mental stress alone
Number of subjects: 0
Study: 7787215

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified sham-feeding (MSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caerulein infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GRP infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of fat to standard meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intragastric application of standard meal of pH 3.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loxiglumide pretreatment with standard meal of pH 6.5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loxiglumide pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCK antagonism
Number of subjects: 0
Study: 3072365

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31837056

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 14
Study: 31050652

Group type: EXPERIMENTAL
Intervention: Acupressure on the Yintang point
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 144

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 144
Study: 28993390

Group type: EXPERIMENTAL
Intervention: Thermal clothing (socks, top and hat)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Thermal clothing
Number of subjects: 91
Study: 25078053

Group type: EXPERIMENTAL
Intervention: Stair-step protocol using clomiphene citrate (CC) 50 mg/day for 5 days, then increased to 100 mg/day for 5 days if nonresponsive.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional protocol using clomiphene citrate (CC) 100 mg/day for patients who failed the 50 mg/day treatment in the previous cycle.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (stair-step and traditional protocol)
Number of subjects: 60
Study: 24336560

Group type: EXPERIMENTAL
Intervention: Call-in centre intervention
Number of subjects: 761
Study: 21978235

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% drops for 3 months (group 1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Primary posterior capsulotomy combined with anterior vitrectomy (group 2)
Number of subjects: 27
Study: 18434561

Group type: EXPERIMENTAL
Intervention: Single-tooth extraction
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tooth brushing
Number of subjects: 151
Study: 16981473

Group type: EXPERIMENTAL
Intervention: Prednisone group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 15632770

Group type: EXPERIMENTAL
Intervention: CR1 (one supervised exercise session per week over 52 weeks)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: CR2 (weekly supervised sessions for 26 weeks followed by one supervised session per month for the remaining 26 weeks)
Number of subjects: 623
Study: 11719356

Group type: EXPERIMENTAL
Intervention: Intravenous Cyclosporine A (CsA)
Number of subjects: 226
Study: 9215828

Group type: COMPARATOR
Intervention: IFN alpha 10 x 10(6) U/m2 subcutaneously on days 1 through 5 and high-dose IL-2 on days 3 through 8 without CDDP (arm A)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: IFN alpha 10 x 10(6) U/m2 subcutaneously on days 1 through 5 and high-dose IL-2 on days 3 through 8 with CDDP 100 mg/m2 on day 1 (arm B)
Number of subjects: 138
Study: 8089640

Group type: EXPERIMENTAL
Intervention: 250 mg of oral terbinafine once daily for 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: 500 mg of oral griseofulvin once daily for 2 weeks
Number of subjects: 64
Study: 3301360

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 20
Study: 30414797

Group type: EXPERIMENTAL
Intervention: PPCI + TH (therapeutic hypothermia)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PPCI alone (Control)
Number of subjects: 50
Study: 28976412

Group type: EXPERIMENTAL
Intervention: Epitiram (generic drug)
Number of subjects: 37
Study: 25639589

Group type: EXPERIMENTAL
Intervention: Crenotherapy with hyperthermal water, rich in mineral salts for 12 days
Number of subjects: 137

Group type: COMPARATOR
Intervention: NaCl 0.9% for 12 days
Number of subjects: 137
Study: 23477959

Group type: EXPERIMENTAL
Intervention: Radical-7 pulse CO-oximeter
Number of subjects: 12
Study: 21815864

Group type: EXPERIMENTAL
Intervention: Telaprevir (3 × 750 mg/day) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telaprevir plus pegylated interferon‐α‐2a (pegIFN‐α‐2a)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegylated interferon‐α‐2a plus placebo
Number of subjects: 0
Study: 19531904

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (healthy men)
Number of subjects: 16
Study: 16618947

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (RT)
Number of subjects: 3083

Group type: COMPARATOR
Intervention: No postmastectomy radiotherapy (no RT)
Number of subjects: 3083
Study: 15142150

Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11217910

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SALM/FP) via hydrofluoroalkane metered-dose inhaler (MDI) 50/100 microg, twice daily
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SALM/FP) via Diskus inhaler 50/100 microg, twice daily
Number of subjects: 497

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg via chlorofluorocarbon MDI, twice daily
Number of subjects: 497